However, after multidisciplinary review, deferral may be offered to patients with asymptomatic brain metastases with either EGFR-mutant NSCLC receiving osimertinib or icotinib, or ALK rearranged NSCLC receiving alectinib, brigatinib, or ceritinib (18). This evidence concerns the gene EGFR and non-small cell lung carcinoma.